Vascular Biogenics (Vascular Biogenics) Margin of Safety % (DCF FCF Based) : N/A (As of May. 05, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Vascular Biogenics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Vascular Biogenics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Vascular Biogenics's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Vascular Biogenics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vascular Biogenics's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vascular Biogenics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Vascular Biogenics's Margin of Safety % (DCF FCF Based) falls into.

Vascular Biogenics Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Vascular Biogenics's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Vascular Biogenics (Vascular Biogenics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vascular Biogenics Ltd (NAS:VBLT) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 HaSatat Street, Modi’in, ISR, 7178106

Website

https://www.vblrx.com

Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.

Executives

Builders Vc Fund I, L.p.	10 percent owner	201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
James Jimin Kim	10 percent owner	C/O NOTABLE LABS, INC., 320 HATCH DRIVE, FOSTER CITY CA 94404
B Capital Group Management, L.p.	10 percent owner	1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Investors Ii Ltd.	10 percent owner	1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Partners Ii, L.p.	10 percent owner	1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Joseph P Wagner	officer: Chief Scientific Officer	320 HATCH DRIVE, FOSTER CITY CA 94404
Tuomo Patsi	director	320 HATCH DRIVE, FOSTER CITY NY 94404
Thomas Bock	director, officer: Chief Executive Officer	320 HATCH DRIVE, FOSTER CITY NY 94404
Michele Galen	director	320 HATCH DRIVE, FOSTER CITY CA 94404
Fr Capital Holdings, L.p.	10 percent owner	2400 MARKET STREET, SUITE 237, PHILADELPHIA PA 19103
B Capital Fund Ii, L.p.	10 percent owner	C/O B CAPITAL GROUP MANAGEMENT, L.P., 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Builders Vc Fund I (canada), L.p.	10 percent owner	201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Builders Vc Entrepreneurs Fund I, L.p.	10 percent owner	201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Dubin Thomas I H	director	C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Peter Feinberg	director	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142